Find the best CNRS technologies to boost your innovative project.
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01
19.10.2018
Medical Diagnostic 08504-01
We can guide you through the whole technology transfer process.
Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.
04731-01
Protein macroarray, Autoimmune disease, Autoantibodies, Ion channels, Neuronal disorders, Diagnosis, prognosis, Screening
French patent application FR1250956 filed on February 1st, 2012, entitled “Puces à protéines, préparation et utilisations”
Franck CHATELAIN
Michel MAZZUCA
Véronique ROGEMOND
Marie Madeleine LARROQUE
Jérôme HONNORAT
Florian LESAGE
Exclusive or non-exclusive licenses, Collaborative agreement
UMR7275 “Institut de Pharmacologie Moléculaire et Cellulaire (IPMC)” Valbonne, France, www.ipmc.cnrs.fr
Recently evidence for autoimmunity towards ion channels in central nervous system disorders has emerged. These disorders include Morvan’s syndrome, Rasmussen’s encephalitis, limbic encephalitis, multiple sclerosis, etc… Detection of such autoantibodies is useful for the diagnosis and classification of these diseases.
This invention provides a unique method for detection of autoantibodies directed against membrane proteins. Anti-ion channel antibodies in the cerebrospinal fluid of patients are detected by using an ion channel macroarray. As a diagnostic tool, the method can be used to detect antibodies directed against specific targets. The method can also be used to identify new ion channel targets in patients that are not positive for antibodies directed against targets already known.
This method has important advantages over current methods that are based on:
– Easier and cheaper
– Not restricted to targets already described
This innovation could be used for multiple applications as:
– Diagnosis and prognosis of autoimmune diseases
– Screening / Identification of new antigenic targets
Accomplished tests: Prototype available. The method has been validated using CSF from patients suffering of encephalitis with anti-NMDA receptor antibodies. 43 patients, 17 of them with anti-NMDAR antibodies detected by immunocytochemistry, were tested. 88% of the positive patients (15/17) were detected using the new method. The specifity for negative patients is 100%.
Current developments: detection of new targets in autoimmune disorders associated with hyperexcitability.
Prototype available
For further information, please contact us (Ref 04731-01)
30.07.2015
Devices & Instruments 03215-01
02.06.2015
Devices & Instruments 04958-01
18.02.2014
Devices & Instruments 05413-01
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01
19.10.2018
Medical Diagnostic 08504-01